Category: BioTech

BioTech

Biotech Stock Report: Reviewing InterMune, Advaxis, Inc & Amgen, Inc

Here in this article, we take a good look at three upcoming Biotech Stocks, namely, InterMune, Advaxis, Inc & Amgen, Inc. InterMune Inc (NASDAQ ITMN) listed its shares as a big mover previous session, as its shares jumped over 35% after Roche AG’s declaration it would buy the respiratory-drug maker for $8.3B, in spite of InterMune’s relatively small array of drugs in its pipeline. According … Continue reading Biotech Stock Report: Reviewing InterMune, Advaxis, Inc & Amgen, Inc

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

SBA Beats Expectations, Raises Guidance Once Again in the First Quarter

SBA Communications SBAC notched another strong firstquarter result, highlighted by better-than-expected earnings and another guidance upgrade. First-quarter revenues grew by 62% year over year to $313 million–roughly 4% above consensus. The growth was driven by a 64.1% increase in the firm’s tower base, which now stands at 17,539. Once again, however, SBA’s growth was in both quality and quantity. The firm was able to expand … Continue reading SBA Beats Expectations, Raises Guidance Once Again in the First Quarter

John MeadyLeave a comment
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

Sohu Posts Solid First-Quarter Results on Strong Top-Line Growth Across All Segments

Chinese Internet firm Sohu SOHU posted first-quarter revenue and earnings that slightly exceeded the firm’s guidance and our internal estimate, thanks to solid top-line growth across brand advertising, search, and gaming. Revenue grew by 36% year over year to $308 million (versus $299 million at the high end of guidance), while non-GAAP net income came in at $24 million (versus $21 million at the high … Continue reading Sohu Posts Solid First-Quarter Results on Strong Top-Line Growth Across All Segments

John MeadyLeave a comment
BioTech, Finance

Biotech Stocks: Invest in Biotech, But at Your Own Risk

Fed Chair Janet Yellen testified before the US Senate Committee on Banking, Housing, and Urban Affairs. She presented the Fed’s semiannual Monetary Policy Report (MPR) to the Congress. In her prepared remarks, she stated that while valuation seems “stretched” in some areas of the bond market, equities “remain generally in line with historical norms.” Yet in the MPR, which bears her signature, the following observation … Continue reading Biotech Stocks: Invest in Biotech, But at Your Own Risk

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

SCA Posts Steady 1Q Results and Sees Early Signs of Improving Construction Market

Swedish consumer goods company Svenska Cellulosa reported first-quarter results that largely tracked our longerterm expectations. SCA’s hygiene operations (personal care and tissue) were once again steady performers while the forest product division lagged as a result of still-weak European demand for paper and solid-wood products. After reviewing the results, we are maintaining our fair value estimate of SEK 136 per share and our no-moat rating. … Continue reading SCA Posts Steady 1Q Results and Sees Early Signs of Improving Construction Market

John MeadyLeave a comment
Biotech stock market news
BioTech, Finance

Biotech Stocks Highlights: A look at Last Week’s Performance

With second quarter earnings season coming to an end, focus in the biotech sector is back on pipeline and regulatory updates. Last week’s highlights included Achillion Pharmaceuticals, Inc.’s (ACHN) impressive interim data on its experimental hepatitis C virus (HCV) treatment, Gilead Sciences’ (GILD – Analyst Report) legal victory and Amgen’s (AMGN – Analyst Report) hit and miss on the clinical front. Achillion, which focuses on … Continue reading Biotech Stocks Highlights: A look at Last Week’s Performance

Richard Atkins